Addressing screams for evidence on renoprotection by GLP-1 receptor agonists.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35065690.
- Also identified by DOI 10.1016/j.kint.2021.11.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although growing evidence supports the benefits of glucagon-like peptide-1 receptor agonists, the renoprotective effects were not fully proven in clinical trials. Now, Xu et al. show that glucagon-like peptide-1 receptor agonists reduce the renal outcome compared with dipeptidyl peptidase-4 inhibitors in a retrospective cohort study of the participants in the Stockholm Creatinine Measurements project undertaken in Stockholm, Sweden. Despite some limitations, the study shows renoprotection by glucagon-like peptide-1 receptor agonists and raises hope about upcoming evidence from prospective clinical trials.
Medical subject headings
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors